Venous Thromboembolism (VTE)

4
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
EDOXABANApproved
edoxaban
Unknown Company
oral

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Vera Therapeutics
Vera TherapeuticsBRISBANE, CA
1 program
1
Experimental: HyperslimPhase 41 trial
Active Trials
NCT06958588RecruitingEst. Mar 2026
DS
Daiichi SankyoChina - Shanghai
2 programs
2
EdoxabanPhase 31 trial
EdoxabanPhase 31 trial
Active Trials
NCT02798471Completed290Est. May 2022
NCT02073682Completed1,046Est. Sep 2017
Bayer
BayerLEVERKUSEN, Germany
1 program
RivaroxabanN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Vera TherapeuticsExperimental: Hyperslim
Daiichi SankyoEdoxaban
Daiichi SankyoEdoxaban

Clinical Trials (3)

Total enrollment: 1,336 patients across 3 trials

NCT06958588Vera TherapeuticsExperimental: Hyperslim

Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis

Start: May 2025Est. completion: Mar 2026
Phase 4Recruiting
NCT02798471Daiichi SankyoEdoxaban

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

Start: Mar 2017Est. completion: May 2022290 patients
Phase 3Completed
NCT02073682Daiichi SankyoEdoxaban

Cancer Venous Thromboembolism (VTE)

Start: Jul 2015Est. completion: Sep 20171,046 patients
Phase 3Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,336 patients
4 companies competing in this space